NO20081218L - Flytende formuleringer - Google Patents

Flytende formuleringer

Info

Publication number
NO20081218L
NO20081218L NO20081218A NO20081218A NO20081218L NO 20081218 L NO20081218 L NO 20081218L NO 20081218 A NO20081218 A NO 20081218A NO 20081218 A NO20081218 A NO 20081218A NO 20081218 L NO20081218 L NO 20081218L
Authority
NO
Norway
Prior art keywords
liquid formulations
glycation
dilution
concentrate
patients
Prior art date
Application number
NO20081218A
Other languages
English (en)
Norwegian (no)
Inventor
Wei-Qin Tong
Vivian Georgousis
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37734410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081218(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20081218L publication Critical patent/NO20081218L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/141—Esters of phosphorous acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
NO20081218A 2005-08-09 2008-03-07 Flytende formuleringer NO20081218L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70682005P 2005-08-09 2005-08-09
PCT/US2006/030836 WO2007021666A2 (fr) 2005-08-09 2006-08-08 Preparations liquides

Publications (1)

Publication Number Publication Date
NO20081218L true NO20081218L (no) 2008-04-29

Family

ID=37734410

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081218A NO20081218L (no) 2005-08-09 2008-03-07 Flytende formuleringer

Country Status (23)

Country Link
US (4) US20080194526A1 (fr)
EP (1) EP1915130B1 (fr)
JP (1) JP5068755B2 (fr)
KR (1) KR101473494B1 (fr)
CN (1) CN101237852B (fr)
AR (1) AR056020A1 (fr)
AU (1) AU2006280138B2 (fr)
BR (1) BRPI0615009A2 (fr)
CA (1) CA2618018C (fr)
EC (1) ECSP088165A (fr)
GT (1) GT200600350A (fr)
IL (1) IL188915A0 (fr)
MA (1) MA29736B1 (fr)
MX (1) MX2008001967A (fr)
MY (1) MY145111A (fr)
NO (1) NO20081218L (fr)
NZ (2) NZ593121A (fr)
PE (2) PE20100149A1 (fr)
RU (2) RU2428180C2 (fr)
TN (1) TNSN08061A1 (fr)
TW (1) TWI317289B (fr)
WO (1) WO2007021666A2 (fr)
ZA (1) ZA200800640B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070085465A (ko) * 2004-11-29 2007-08-27 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
MY171061A (en) 2005-11-09 2019-09-24 Onyx Therapeutics Inc Compounds for enzyme inhibition
CA2657213C (fr) 2006-06-19 2017-01-03 Proteolix, Inc. Peptides epoxycetones pour l'inhibition de proteasomes
KR20170125413A (ko) 2007-10-04 2017-11-14 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
EP3733161A1 (fr) * 2007-10-12 2020-11-04 Novartis AG Compositions comprenant des modulateurs de récepteur de sphingosine 1 (s1p) phosphate
JP2011525189A (ja) * 2008-06-20 2011-09-15 ノバルティス アーゲー 多発性硬化症を治療するための小児科の組成物
EP3090737A1 (fr) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Thérapie de combinaison avec peptides d'époxycétones
JP2012508215A (ja) 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
JP2012512884A (ja) 2008-12-18 2012-06-07 ノバルティス アーゲー １−（４−｛１−［（ｅ）−４−シクロヘキシル−３−トリフルオロメチル−ベンジルオキシイミノ］−エチル｝−２−エチル−ベンジル）−アゼチジン−３−カルボン酸の新規の多形相
KR20110101159A (ko) * 2008-12-18 2011-09-15 노파르티스 아게 신규 염
US20120115840A1 (en) * 2008-12-18 2012-05-10 Lech Ciszewski Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid
JP2012518671A (ja) * 2009-02-24 2012-08-16 ノバルティス アーゲー セラミド類似体代謝物
US20100243087A1 (en) * 2009-03-03 2010-09-30 Millipore Corporation System and pump apparatus for processing fluid samples
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
EP2542238B1 (fr) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Composés pour inhibition de l'immunoprotéasome
JP6111202B2 (ja) 2011-01-07 2017-04-05 ノバルティス アーゲー 免疫抑制製剤
WO2012095853A1 (fr) 2011-01-10 2012-07-19 Novartis Pharma Ag Formulations à libération modifiée comprenant des modulateurs des récepteurs sip
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
EP3027174B1 (fr) 2013-07-29 2019-07-24 Aizant Drug Research Solutions Private Limited Compositions pharmaceutiques à base de fingolimod
WO2016042493A1 (fr) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Compositions pharmaceutiques de fingolimod
WO2016135644A1 (fr) 2015-02-26 2016-09-01 Novartis Ag Traitement de maladie auto-immune chez un patient recevant en outre un bêtabloquant
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
CA3074043A1 (fr) 2017-09-27 2019-04-04 Novartis Ag Formulation parenterale comprenant du sitomod
EP3687531A1 (fr) 2017-09-29 2020-08-05 Novartis AG Schéma posologique de siponimod
CA3073910A1 (fr) 2017-09-29 2019-04-04 Novartis Ag Schema posologique de siponimod
WO2021214717A1 (fr) 2020-04-23 2021-10-28 Novartis Ag Schéma posologique pour l'utilisation de siponimod pour le traitement du syndrome de détresse respiratoire aiguë

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69321823T2 (de) * 1992-10-21 1999-06-02 Taito Co., Ltd., Tokio/Tokyo 2-amino-1, 3- propandiolverbindung und immunosuppressium
DE19645549A1 (de) * 1996-11-05 1998-05-07 Bayer Ag Verfahren zur Herstellung von 2-Methyl-2,4-diaminopentan
ES2240868T3 (es) * 1997-04-04 2005-10-16 Mitsubishi Pharma Corporation Compuesto de 2-aminopropano -1,3-diol, su uso farmaceutico e intermedios en su sintesis.
US6727283B2 (en) * 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
EP1424078A4 (fr) * 2001-09-04 2009-03-25 Ono Pharmaceutical Co Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate
CA2461212C (fr) * 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Derive de sulfure de diaryle, sels correspondant et agents immunosuppresseur utilisant ces derives
DE60235900D1 (de) * 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
US20040058894A1 (en) * 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
PT1505959E (pt) * 2002-05-16 2009-02-05 Novartis Ag Utilização de agentes de ligação do receptor edg em cancro
US20070043014A1 (en) * 2003-10-01 2007-02-22 Merck & Co., Inc. 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists

Also Published As

Publication number Publication date
RU2008108887A (ru) 2009-09-20
US20080194526A1 (en) 2008-08-14
US20140179636A1 (en) 2014-06-26
WO2007021666A3 (fr) 2007-05-31
CN101237852B (zh) 2011-01-26
BRPI0615009A2 (pt) 2011-05-03
ZA200800640B (en) 2008-12-31
US20160030572A1 (en) 2016-02-04
EP1915130B1 (fr) 2016-07-13
MY145111A (en) 2011-12-30
MX2008001967A (es) 2008-03-26
MA29736B1 (fr) 2008-09-01
GT200600350A (es) 2007-03-28
HK1123188A1 (en) 2009-06-12
NZ565696A (en) 2011-06-30
JP2009504653A (ja) 2009-02-05
EP1915130A2 (fr) 2008-04-30
TWI317289B (en) 2009-11-21
CA2618018C (fr) 2016-05-31
RU2470631C2 (ru) 2012-12-27
RU2428180C2 (ru) 2011-09-10
KR20080035608A (ko) 2008-04-23
IL188915A0 (en) 2008-04-13
NZ593121A (en) 2012-09-28
KR101473494B1 (ko) 2014-12-16
RU2011106364A (ru) 2012-08-27
US20120328664A1 (en) 2012-12-27
PE20100149A1 (es) 2010-03-24
TNSN08061A1 (en) 2009-07-14
ECSP088165A (es) 2008-03-26
US20150080347A9 (en) 2015-03-19
CA2618018A1 (fr) 2007-02-22
TW200738277A (en) 2007-10-16
PE20070337A1 (es) 2007-04-18
AR056020A1 (es) 2007-09-12
WO2007021666A2 (fr) 2007-02-22
CN101237852A (zh) 2008-08-06
AU2006280138A1 (en) 2007-02-22
AU2006280138B2 (en) 2010-03-04
JP5068755B2 (ja) 2012-11-07

Similar Documents

Publication Publication Date Title
NO20081218L (no) Flytende formuleringer
CY1113159T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
CY1110922T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
NO20093146L (no) Amino-pyridinderivater som S1P1/EDG1-reseptoragonister
NO20074567L (no) Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse
NO20074295L (no) Substituerte gamma lactamer som terapeutiske midler
UY30460A1 (es) Compuestos terapéuticos
DK2451445T3 (da) Fremgangsmåde til at tørre bibw2992, dets salte og faste farmaceutiske formuleringer omfattende denne aktive ingrediens
WO2007087548A3 (fr) Composés chimiques
NO20070213L (no) Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser
CY1115176T1 (el) Ρυθμιστες υποδοχεων τυπου toll
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
ECSP088296A (es) Compuestos terapéuticos
CY1108690T1 (el) Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων
NO20100250L (no) Farmasoytisk preparat som innbefatter en S1P reseptoragonist og en sukkeralkohol, og framgangsmate til fremstilling derav
NO20063430L (no) Generelt lineaer, brusende oral fentanyl doseringsform, og metoder for administrering
ATE457979T1 (de) Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate
NO20056132L (no) Krystallinsk form av beta2 adrenergisk receptoragonist
GT200600496A (es) Sales, profarmacos y formulaciones de 1-[5-(4-amino-7-isopropil-7h-pirrolo[2,3-d]piirimidin-5-carbonil)-2-metoxi-feil]-3-(2,4-dicloro-fenil)-urea.
GT200500309A (es) Derivados de sulfonilbencilimidazol
WO2006025070A3 (fr) Nebivolol et ses sels pharmaceutiquement acceptables, procede de preparation et compositions pharmaceutiques de nebivolol
NO20054868L (no) CaSr antagonist
NO20082097L (no) Farmasoytiske sammensetninger
WO2006081363A3 (fr) Formulations orales pour l'administration de butanes catecholiques comprenant des composes ndga
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application